PT Kalbe Farma Tbk stock analysis
Want to see PTKFY full AI Analyst Report?
PT Kalbe Farma Tbk (PTKFY) Stock Price & Analysis
PTKFY Stock Chart & Stats
- Day’s Range
- $8.66 - $8.66
- 52-Week Range
- $7.26 - $15.07
- Previous Close
- $8.49
- Volume
- N/A
- Average Volume (3M)
- 510
- Market Cap
- $2.03B
- Enterprise Value
- $1.63B
- Total Cash (Recent Filing)
- $5.58T
- Total Debt (Recent Filing)
- $295.23B
- Price to Earnings (P/E)
- 9.5
- Beta
- 0.60
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 05, 2026
- Dividend Yield
- 2.31%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage gives Kalbe Farma substantial financial flexibility and limits balance-sheet risk. Combined with consistently healthy returns on equity, this indicates the company generates attractive profits from its capital base without relying heavily on debt, supporting resilience and future investment capacity.
Steady Revenue And Earnings Base
Multi-year revenue expansion and continued positive profitability demonstrate a durable operating base across Kalbe Farma’s healthcare activities. Although growth has moderated, ongoing sales progression and a solid net margin provide recurring earnings support and a foundation for continued business development.
Diversified Healthcare Portfolio
Kalbe Farma’s presence across prescription and over-the-counter medicines, consumer health, nutrition, devices, and distribution diversifies its sources of demand. This broad healthcare platform can support business durability by reducing dependence on a single product category or customer need over time.
Bears Say
Margin Compression
The decline in gross and net margins from 2021–2022 levels signals pressure on profitability quality even though earnings remain solid. If this trend persists, it could limit operating leverage, reduce the benefit of revenue growth, and constrain the pace at which profits compound.
Moderating Growth
A slower recent growth trajectory reduces the near-term expansion rate of Kalbe Farma’s revenue and earnings base. Continued moderation would make it harder to absorb fixed costs, sustain prior profitability levels, or generate the same improvement in shareholder returns achieved during stronger growth periods.
Uneven Cash Conversion
Positive free cash flow supports the business, but volatility and weaker recent operating cash flow indicate that reported profits are not converting consistently into cash. Working-capital or timing effects could therefore make internally funded investment and shareholder distributions less predictable across periods.
PT Kalbe Farma Tbk News
PTKFY FAQ
What was PT Kalbe Farma Tbk’s price range in the past 12 months?
What is PT Kalbe Farma Tbk’s market cap?
When is PT Kalbe Farma Tbk’s upcoming earnings report date?
How were PT Kalbe Farma Tbk’s earnings last quarter?
Is PT Kalbe Farma Tbk overvalued?
Does PT Kalbe Farma Tbk pay dividends?
What is PT Kalbe Farma Tbk’s EPS estimate?
How many shares outstanding does PT Kalbe Farma Tbk have?
What happened to PT Kalbe Farma Tbk’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PT Kalbe Farma Tbk?
What is the TipRanks Smart Score and how is it calculated?
PT Kalbe Farma Tbk Stock Smart Score
Company Description
PT Kalbe Farma Tbk
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Bernadette Ruth Irawati Setiady
- Employees
- 12,835
- Website
- www.kalbe.co.id
- Address
- Gedung KALBE, Jakarta, JK, 10510, ID
PT Kalbe Farma Tbk (PTKFY) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 2 | 6 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 10 | 0 | 2 |



